Another nail in the AML coffin

Blood

Volumn 113, Issue 24, 2009, Pages 6045-6046

  Abboud, Camille N ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; N [1,4,8,11 TETRAAZACYCLOTETRADECANYL 1,4 PHENYLENEBIS(METHYLENE)] 2 (AMINOMETHYL)PYRIDINE; PLERIXAFOR; STROMAL CELL DERIVED FACTOR 1;

ACUTE GRANULOCYTIC LEUKEMIA; CHEMOSENSITIZATION; DRUG ACTIVITY; DRUG RESEARCH; DRUG TARGETING; HUMAN; NONHUMAN; NOTE; PRIORITY JOURNAL;

EID: 70449475491     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-03-189803     Document Type: Note

References (21)

1. Broxmeyer HE. Chemokines in hematopoiesis. Curr Opin Hematol 2008;15:49-58.
2. Burger JA, Peled A. CXCR4 antagonist: targeting the microenvironment in leukemia and other cancers. Leukemia. 2009;23:43-52.
3. Raaijmakers MHGP, Scadden DT. Evolving concepts on the microenvironmental niche for hematopoietic stem cells. Curr Opin Hematol. 2008;15:301-306.
4. Colmone A, Amorim M, Pontier AL, et al. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science. 2008;322:1861-1865.
5. Christopher MJ, Liu F, Hilton MJ, Long F, Link DC. Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokine-induced mobilization. Blood. Prepublished on January 13, 2009, as DOI 10.1182/blood-2008-10-18754.
6. Stewart DA, Smith C, MacFarland R, et al. Pharmakokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biol Blood Marrow Transpl. 2009;15:39-49.
7. Nervi B, Ramirez P, Rettig MP, et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood. 2009;113:6206-6214.
8. Uy GL, Rettig MP, McFarland KM, et al. Mobilization and chemosensitization ofAMLwith the CXCR4 antagonist plerixafor (AMD3100): A phase I/II study of AMD3100+-MEC in patients with relapsed or refractory disease [abstract]. Blood. 2008;112;678. Abstract 1944.
9. Papayannolpoulou T, Scadden D. Stem cell ecology and stem cells in motion. Blood. 2008;111:3923-3930.
10. Zohren F, Toutzaris D, Klärner V, et al. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+- hematopoietic progenitor cells in humans. Blood. 2008;111:3893-3895.
11. Bonig H, Wundes A, Chang K-H, et al. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood. 2008;111:3439-3441.
12. Theien BE, Vanderlugt CL, Nickerson-Nutter C, et al. Differential effects of treatment with a small-molecule VLA-4 antagonist before and after onset of relapsing EAE. Blood. 2003;102:4464-4471. (Pubitemid 37494111)
13. Small D. Targeting FLT3 for the treatment of leukemia. Semin Hematol. 2008;45:S17-S21.
14. Spoo AC, Lübbert M, Wierda WG, et al. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood. 2007;109:786-791. (Pubitemid 46105982)
15. Zeng Z, Shi YX, Samudio IJ, et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood. 2009;113:6215-6224.
16. Safaian NN, Czibere A, Bruns L, et al. Sorafenib (Nexavar®) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+-+acute myeloid leukemia. Leuk Res. 2009;33:348-350.
17. Jin L, Hope KJ, Zhai Q, et al. Targeting of CD44 eradicates human acute myeloid leukemia stem cells. Nat Med. 2006;12:1167-1174. (Pubitemid 44527352)
18. Matsunaga T, Takemoto N, Sato T, et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med. 2003;9:1158-1165. (Pubitemid 37173700)
19. Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14:1777-1784. (Pubitemid 30756775)
20. Misaghian N, Ligresti G, Steelman LS, et al. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia. 2009;23:25-42.
21. Ley TJ, Mardis ER, Ding L, et al. DNA sequencing of a cytogenetically normal acute myeloid leukemia genome. Nature. 2008;456:66-72.